452 / 1778
- 60 patients from 25 institutions were enrolled between 2006 and 2009
- 49 patients evaluable.
- Median follow-up of 10 months (Mostly IIB 63%, squamous-80% ) no treatment-
related SAEs.
- There were 15 (31%) protocol specified treatment-related AEs, most common were
hematologic (12/15 =80%)
BIOLOGIC AGENTS -
BEVACIZUMAB
Phase II study of Bevacizumab in combination with
definitive radiotherapy and cisplatin in locally advanced cervical carcinoma
(RTOG 0417)
2010 ASCO Annual Meeting: J Clin Oncol 28:15s, 2010 (suppl; abstr 5006)